ABSI Company Profile and Key Details

Absci Corporation generated EPS of -$0.90 over the past year. Five-year average earnings growth is -29.3%. Wall Street analysts project EPS growth of 9.94% annually over the next five years. The latest quarter delivered EPS of -$0.21. The next quarter is forecast at -$0.18. Next year's EPS is expected at $32.66. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $7.00. The high target offers 96.53% upside. The low target suggests -19.08% downside. The mean target is $10.50. This offers 21.39% upside. Absci Corporation earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 9.94%. The prior quarter beat by -5.0%. Over the last six quarters, Apple has recorded several small beats. These include -8.7% in May 13, 2025.

ABSI has shown weak momentum, losing -14.71% over the past week and -35.98% over the past quarter, though year-to-date performance is down -16.91%. Short-term trend indicators are mixed aligned (SMA20 2.3%, SMA50 -9.81%, SMA200 -9.25%). The stock’s 14-day RSI is 48.85 (neutral), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.25% below its high and over 39.8% above its low. Average 10-day trading volume of 2.98 million shares is below the 3-month average of 4.60 million, indicating normal recent market interest.

Absci Corporation has 171.61 million shares outstanding. The public float is 163.81 million shares, elevated short interest at 26.53% of float. This equals 37.42 million shares. The short ratio is 12.74 days. Institutional investors hold 83.06% of the float. Insiders own 12.04%. Phoenix Venture Partners II LP holds 11.28 million shares, McClain Sean has 8.33 million shares and Redmile Group, LLC has 8.25 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Absci Corporation (NASDAQ:ABSI) closed at $8.16 USD, losing -$0.49 (-5.70%) from the previous close of $8.65. The stock is currently mid-range between its 52-week high and low $2.24 and $12.05. With a market capitalization of about $1.38 billion, Absci Corporation is classified as a small-cap and shows higher-than-market volatility (beta ~2.44). Key stats such as the average daily volume over the past year has been around 4.59 million shares, volume is running light vs its 52-week average. Headquartered in Vancouver, WA, Absci Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sean McClain, the company employs approximately 140 people and listed since July 22, 2021. Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds.

Absci Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.

Absci Corporation (NASDAQ:ABSI) shares are down -16.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Absci Corporation trading at a premium to the broader market with a P/E of -10.94. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.61, suggesting 11.1% upside. Our AI forecast model points to short-term strength (0.92% over two weeks), a medium-term rise (148.79% over three months), and a longer-term gain (330.52% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Absci Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.92%, with price expected at $8.73 by September 23, 2026, within a range of $8.15 to $9.23 3-Month Outlook: Projected rise of 148.79%, reaching $21.52 by December 08, 2026, with a range of $21.36 to $21.66. 1-Year Outlook: Projected gain of 330.52%, with price at $37.24 by September 09, 2027, within a range of $40.67 to $45.95.

Absci Corporation trades at a P/E ratio of -10.94, slightly below the S&P 500 average, with a price-to-sales ratio of 949.93 and a price-to-book ratio of 5.6 trading at moderately above to book value. The P/FCF stands at -13.61, also below market averages.